Skip to content
HowShorted

AMAG PHARMACEUTICALS, INC. short interest in 2019

In 2019, AMAG PHARMACEUTICALS, INC.'s disclosed short interest ran from 26.15% of shares outstanding on 15 Jan 2019 to 43.06% on 31 Dec 2019, a change of +16.91 percentage points. The year's high was 44.55% on 13 Dec 2019 and its low 24.47% on 30 Apr 2019, averaging 33.11% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 31.58 days on 31 Dec 2019. Full history: AMAG PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020

Aggregate net short position time series for AMAG PHARMACEUTICALS, INC. in 2019

2019 in figures

Start of year
26.15% (15 Jan 2019)
End of year
43.06% (31 Dec 2019)
Change
+16.91 pp
High
44.55% (13 Dec 2019)
Low
24.47% (30 Apr 2019)
Average
33.11%
Highest days to cover
31.58 (31 Dec 2019)
SEC filings marked
9

Every report in 2019

AMAG PHARMACEUTICALS, INC. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 201926.15%12.84results (8-K)
31 Jan 201925.13%18.84
15 Feb 201925.16%14.84results (8-K)
28 Feb 201924.63%18.69
15 Mar 201924.97%5.4710-K filed
29 Mar 201925.83%17.77
15 Apr 201925.01%20.88
30 Apr 201924.47%15.07
15 May 201926.92%10.59results (8-K), 10-Q filed
31 May 201925.11%12.51
14 Jun 201925.20%15.27
28 Jun 201931.30%5.47
15 Jul 201930.92%15.63
31 Jul 201933.85%13.70
15 Aug 201943.20%5.5710-Q filed, results (8-K)
30 Aug 201942.98%13.69
13 Sep 201942.17%15.57
30 Sep 201942.03%18.91
15 Oct 201939.56%20.11
31 Oct 201939.25%12.98
15 Nov 201941.70%15.7410-Q filed, results (8-K)
29 Nov 201941.43%22.93
13 Dec 201944.55%30.80
31 Dec 201943.06%31.58

See also: AMAG PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.